98%
921
2 minutes
20
Purpose: This study aimed to develop and validate 2 preoperative ultrasound (US)-based risk-scoring systems to predict axillary lymph node (ALN) metastasis and the number of metastatic ALNs (≤ 2 vs. > 2) in patients with breast cancer.
Method: A multicenter retrospective study included 1194 women with breast cancer from 3 institutions. Institutions 1 and 2 were used for training (n = 643) and testing (n = 275), while 276 patients from Institution 3 served as the validation set. Multivariate logistic regression was used to construct 2 risk-scoring systems based on US features. Predictive performance was assessed using area under the curve (AUC), calibration plots, and decision curve analysis.
Results: The risk-scoring system for ALN metastasis (presence vs. absence), based on the longest diameter and margin of the mass, mass pathology, long-to-short axis ratio of the ALN, cortical morphological features, and blood flow type of the ALN, achieved AUCs of 0.86, 0.81, and 0.84 in the training, testing, and validation sets, respectively. The risk-scoring system for predicting the number of metastatic ALNs (≤ 2 vs. >2), based on US (the longest diameter and the number of suspicious ALNs on US), achieved AUCs of 0.78, 0.75, and 0.78 in the training, testing, and validation sets, respectively. Calibration plots showed good model calibration, and decision curve analysis confirmed the clinical utility of both models.
Conclusion: The 2 preoperative US-based risk-scoring systems effectively predicted ALN metastasis and the number of metastatic ALNs, aiding clinicians in assessing the risk of ALN involvement in breast cancer patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clbc.2025.06.007 | DOI Listing |
Mol Cancer Ther
September 2025
Case Western Reserve University School of Medicine, Cleveland, OH, United States.
The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor down-regulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor.
View Article and Find Full Text PDFJ Med Chem
September 2025
Department of Natural Products and Medicinal Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India.
Nitric oxide (NO) is a multifunctional signaling molecule in oncology, influencing tumor progression, apoptosis, and immune responses. In contrast, chlorambucil (Cbl), a DNA-alkylating chemotherapeutic, induces cytotoxicity through DNA damage. Here, we report a photoresponsive nanoparticle platform for sequential codelivery of NO and Cbl, where NO is released within 10 min of irradiation, followed by Cbl release within 30 min.
View Article and Find Full Text PDFJ Am Acad Audiol
September 2025
Paraneoplastic cerebellar degeneration (PCD) is a rare neurological disorder caused by tumor-mediated antibodies targeting the cerebellum, often leading to irreversible cerebellar damage. The most common antibody implicated in PCD is anti-Purkinje cell cytoplasmic antibody type-1, associated with malignancies such as breast, gynecological, and lung cancers. Symptoms often include dizziness, imbalance, progressive ataxia, and other cerebellar signs/symptoms, but early presentations may mimic acute vestibular syndrome, thus complicating diagnosis.
View Article and Find Full Text PDFStem Cell Rev Rep
September 2025
Paris Cité University, INSERM UMR-S 970, Paris Cardiovascular Research Centre, Paris, France.
Endothelial Colony-Forming Cells (ECFCs) are recognized as key vasculogenic progenitors in humans and serve as valuable liquid biopsies for diagnosing and studying vascular disorders. In a groundbreaking study, Anceschi et al. present a novel, integrative strategy that combines ECFCs loaded with gold nanorods (AuNRs) to enhance tumor radiosensitization through localized hyperthermia.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.